to the European Medicines Agency (EMEA) for Focetria as an H5N1 . Focetria is a pandemic influenza vaccine, surface antigen, inactivated. Focetria. Scientific conclusions and grounds recommending the variation to the terms of the marketing EMEA/H/C//PSUV/ following assessment of the H1N1 data available with Focetria in children, In the context of variation EMEA/H/C//II/ (commission.
|Country:||Sao Tome and Principe|
|Genre:||Health and Food|
|Published (Last):||13 August 2006|
|PDF File Size:||2.83 Mb|
|ePub File Size:||2.65 Mb|
|Price:||Free* [*Free Regsitration Required]|
Pandemic influenza: news archive
The marketing authorisation for Focetria has been expired following the marketing-authorisation holder’s decision not to apply for a renewal. More detail is available in the summary of product characteristics.
Skip to main content. Veterinary regulatory Overview Research and development Marketing authorisation Post-authorisation. Table of contents Overview Authorisation details Product information Assessment history.
Product details Name Focetria. Emes virus surface antigens haemagglutinin and neuraminidase of strain: You are therefore advised to be selective about which sections or pages you wish to print.
Prophylaxis of influenza focegria by A H1N1v virus. Focetria should be used in accordance with official guidance. Changes since initial authorisation of medicine List item.
Pandemic influenza: news archive | European Medicines Agency
Initial marketing-authorisation documents List item. More information on Focetria. How useful was this page?
Leave this field blank. International non-proprietary name INN or common name.
Focetria | European Medicines Agency
Influenza, Human Immunization Disease Outbreaks. Anatomical therapeutic chemical ATC code.
Novartis Vaccines and Diagnostics S. Date of issue of marketing authorisation valid throughout the European Union.